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individuals. Unlike the control, DA-enhanced Th17 cytokine production in GAD individuals was not affected
by glucocorticoid. In conclusion, our results show that the T cell functional dysregulation in GAD individuals is
signiﬁcantly ampliﬁed by DA. These immune abnormalities can have impact in increasing the susceptibility of
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It is now known that the immune system is regulated by central as
well as peripheral sympathetic nervous system. This is primarily
achieved by cathecolamines, such as dopamine (DA), which interact
with different effector immune cells and thereby ultimately regulate
the homeostatic response of an individual to environmental stresses
(Sarkar et al., 2010).
In the central nervous system, DA plays an essential role as
neurotransmitter by playing diverse functions including movement
(Cenci, 2007), drug addiction (Dayan, 2009), pain perception (Potvin et
al., 2009), hormone secretion (Ben-Jonathan and Hnasko, 2001),
motivation and pleasure (Wise, 2008). At the peripheral level,
sympathetic innervations of organs and tissues, such as lymph nodes
and spleen, can be controlled by dopaminergic signaling, particularly
during stress (Bencsics et al., 1997).DA exerts its effects in susceptible cells by stimulating DA receptors
(DARs) expressed on the cell surface of neurons. Five DARs have been
described so far (D1–D5); DARs are hepta-spanning membrane
receptors and belong to the superfamily of the G protein-coupled
receptors (Strange, 1993). Whereas type I DARs (D1 and D5) are
generally coupled to Gαs and stimulate cAMP production, type II DARs
(D2, D3 and D4) are often coupled to Gαi promoting inhibition of cAMP
synthesis (Sibley et al., 1993). This differential coupling of DARs allows
DA to promote distinct effects in the same cell expressing the two
different kinds of DARs.
Besides its conventional role as neurotransmitter, DA is now
considered to play a pivotal role in neuroimmune communications.
The ﬁrst clue to this possibility was the observation that DARs are
expressed in normal human leukocytes (McKenna et al., 2002; Ferrari et
al., 2004; Kirillova et al., 2008; Nakano et al., 2008, 2009). Interestingly,
in schizophrenic patients, who have a hiperdopaminergic activity
(Birtwistle and Baldwin, 1998), severe abnormalities of immune
functions have been demonstrated, such as alterations in T-cell subsets,
production of cytokines, and effector functions (Muller et al., 2000;
Strous and Shoenfeld, 2006; Riedel et al., 2007). Furthermore, it is
known that psychological stress causes an increase in peripheral release
of DA (Sinha, 2008), and individuals suffering from chronic stress, like
those with generalized anxiety disorder (GAD), are more susceptible to
infectious diseases by damaging Th1-mediated immune response
(Boscarino, 2004; Koh and Lee, 2004; Sareen et al., 2005; Schneiderman
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2007). On the other hand, anxiety disorders are also known to
contribute to the pathogenesis of many inﬂammatory/autoimmune
diseases by elevating systemic production of IL-1, IL-6 and TNF-α
cytokines (Afﬂecket al., 1997;Wessa andRohleder, 2007; Lemieuxet al.,
2008; Gill et al., 2009).
Generalized anxiety disorder (GAD) is a common chronic disorder
characterized by long-lasting anxiety that is not focusedon any object or
situation. Patients suffering from generalized anxiety experience
persistent non-speciﬁc fear and worry, and become over-concerned
with everyday matters (Khouzam, 2009). They are prone to ﬂare up in
moments of high stress and frequently present psychosomatic
symptoms such as headache, sweating, muscle spasms, palpitations,
and hypertension, which, in some cases, severely compromise their
qualityof life. Theprevalence ofGAD in theUSA(Kessler et al., 2005) and
in Brazil (Andrade et al., 2002) was estimated in 1.3–2.8% adults, and,
until now, no information is available on the effect of DA on T-cell
functions in anxious subjects. Therefore, the objective of this work was
to explore the impact stress-related doses of DA on T cell proﬁle
following in vitronon-speciﬁc activation in a groupofpatientswithGAD.
2. Methods
2.1. Participants
Twenty individuals with generalized anxiety disorder (8 male, 12
female; mean age=29.4 years, SD=12.7, range 17–42) and 20
healthy subjects without any detectable psychiatric disorder matched
by age (mean age=29.7 years, SD=10.3, range 19–40), gender,
racial background and annual income were recruited to participate
this study (Table 1). We used the Spielberger State (STAIS) and Trait
(STAIT) Anxiety Inventory (Kohn et al., 2008), Hamilton Depression
Rating scale (HAMD) and Hamilton Anxiety Rating scale (HAMA) to
measure mood states in all subjects (Hamilton, 1959). Individuals
with a present, past and family history of mental disorders were
assessed through the Semi structured Interview for the DSMIII-R
(SCID) (Spitzer et al., 1992). According to the HAMA, we included only
the patients with moderate–severe symptoms of anxiety.
Subjects were excluded if they reported intake of any medication
with immune-modulating effects, such as glucocorticoids, had acute or
chronic organic illnesses, or met criteria for additional mental disorders
other than anxiety or stress-related affective disorders. Anxiety
disorders often co-exist with other mental disorders, particularly
clinical depression, which may occur in as many as 60% of people with
anxiety. In our study, 05/20 among anxiety patients met the DSM-IV
criteria for current major depressive episode, however, they were notTable 1
Characteristics of the subjects.
Controla (n=20) GADb (n=20)
Mean age in years (sd) 29.4 (12.7) 20.7 (10.3)
Male (%) 50 40
Mean BMI (sd)c 25.4±4.7 23.2±5.8
BCG vaccine (%) 100 100
PPD skin test positive (%)d 85 75
CD4 T cell (%)e 49.3±5.1 50.1±4.4
CD8 T cell (%) 24.6±10.3 26.1±7.6
B cell (%) 18.2±3.8 18.7±5.1
Monocytes (%) 8.3±2.2 9.6±2.6
a Healthy individuals.
b Generalized anxiety disorder individuals.
c Body mass index.
d Individuals that reacted to standard dose of 5 Tuberculin units (0.1 mL) injected
intradermally. It is considered a skin positive reaction when the diameter of induration
is N4 mm (read 48 to 72 h later). None of subjects had active pulmonary TB.
e Percentage of PBMC subsets.excluded because no signiﬁcant differencewas observed between them
and theother non-depressiveanxious individuals concerning the results
from immune function analysis. Although 14/20 anxious patients
reported past intake of psychotropic medication (12 anxiolytics and 2
antidepressants), all participants were completely medication-free for
at least 6 months prior to blood sampling. Of note, none of the women
was pregnant or lactating. Finally, the Survey of Immunological and
General Health (SIGH) was used as a self-report measure of physical
health (Kang et al., 1991). The SIGH also includes questions on age,
weight, and demographic background and has been successfully used in
a wide variety of studies (Kang et al., 1991; Strauman et al., 1993;
Lemieux and Coe, 1995). Body Mass Index (BMI), that might affect
immune function, was calculated as weight in kilograms divided by the
square of height in meters. For our study, all subjects had BMIs ranging
from 18 to 30 (Table 1). To study the impact of dopamine (DA) on the in
vitro immunological events induced by recall antigen, we selected
individuals from both groups who had a positive puriﬁed protein
derivative (PPD) skin test (induration N4–10 mm). Of note, none of the
PPD-positive subjects had active pulmonary tuberculosis (excluded by
normal chest x-ray).
After a complete description of the study to the participants,
written informed consent was obtained for each individual. The study
was approved by the Ethical Committee for Research on Human
Subjects of the Federal University of the State of Rio de Janeiro
(UNIRIO). Finally, all immunological evaluations shown here were
performed twice in each individual from blood samples collected in
different times.
2.2. Isolation of plasma and PBMC
The peripheral blood (20 mL) from healthy (control, n=20) and
anxious patients (GAD, n=20) were drawn between 10 and 11 a.m.
into tubes containing heparine (BD Vacutainer, Franklin Lakes, NY).
Immediately after blood collection, an aliquot (2 mL) was separated
for obtaining the total plasma for systemic cytokine quantiﬁcation by
ELISA. The remaining blood was used to obtain the peripheral blood
mononuclear cells (PBMC) by centrifugation on Ficoll–Hypaque
density gradients. The PBMC were collected and washed three times
in HANK's solution. The total cells were then suspended in 1 mL of
RPMI-1640 and the number of viable cells was measured by trypan
blue exclusion using a hemocytometer.
2.3. Immunoﬂuorescence labeling and ﬂow cytometry
In order to determine the percentage of CD4+ T cells, CD8+ T cells,
B cells and monocytes among whole PBMC, 50 μL of PBMC were
incubated for 20 min with antibodies (Abs) anti-CD3-FITC, CD4-PE,
CD8-APC, anti-CD19-FITC, and anti-CD14-PE. All the Abs were
obtained from BD PharMingen. Labeled cells were analyzed by using
FACSCalibur ﬂow cytometer and CellQuest software (BD Biosciences,
Mountain View, CA). With each sample, a negative control with
isotype-matched control Abs was used to determine the positive and
negative cell populations.
2.4. Cell cultures and stimulus
For functional immuneexperiments, viable PBMC(1×106/mL)were
cultured either in a 96-well ﬂat-bottomed microplates with 0.2 mL of
complete RPMI 1640mediumor in a 24-well ﬂat-bottomedmicroplates
with 1 mL of complete RPMI 1640 medium. The RPMI 1640 was
considered complete when it was added with 2 mM of L-glutamine
(GIBCO, Carlsbad, CA, USA), 10% of FCS, 20 U/mL of penicillin, 20 μg/mL
of streptomycin and 20 mM of HEPES buffer. In order to induce T cell
polyclonal activation, whole PBMC cultures (1×106/mL) were main-
tained for 3 days with phytohemaglutinin (PHA, 1 μg/mL), which
correspond the time of maximal T cell activation by this mitogen. To
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test positive individuals were maintained for 5 days in the presence of
PPD (15 μg/mL) (RT48, Statens Serum Institut, Copenhagen, Denmark).
The endotoxin content of PPD solution was b0.02 ng/mg, as assessed by
a chromogenic Limulus lysate assay (BioWhittaker). The effect of
dopamine (DA) on either PHA- or PPD-induced immune events was
evaluated following addition of DA in stress-related doses (1×10−7 and
1×10−6 M) (Maestroni and Mazzola, 2003; Cosentino et al., 2004). To
evaluate the effect of glucocorticoid (GC), 1×10−6 M or 1×10−5 M of
dexamethasone (DEX) (Sigma Chemicals, St Loius, MD) was added to
some wells at the beginning of cell cultures. We chose these GC
concentrations because they have been related to stress-induced
endogenous cortisol release (Agarwal andMarshall, 1998). Importantly,
both DA and DEX concentrations used here did not induce cell death
(data not shown). All cellswere cultured at 37 °C in a humidiﬁed 5% CO2
incubator. Of note, the results shown in this study are representative of
two experiments done in different times for each individual.Control GAD
0
15000
30000
45000
60000
None
DA (1 x 10-6 M)
PHA
PHA + DA (1 x 10-6 M)
p < 0.0001
p < 0.0001
p = 0.867
A
PHA + DA (1 x 10-7 M)
p = 0.0017
cm
p
Control GAD
0
25
50
75
100
PHA
PHA + DA (1 x 10-6 M)
B
p < 0.0001
p < 0.0001
PHA + DA (1 x 10-7 M)
Vi
ab
ili
ty
 (%
)
Fig. 1. The effect of dopamine (DA) on in vitro proliferative response and cell viability in
anxious and non-anxious subjects in response to T cell polyclonal activator. PBMC
(1×106/mL) puriﬁed from anxious (GAD, n=20) and non-anxious (control, n=20)
individuals were kept in culture with only medium (none) or with PHA (1 μg/mL) for
3 days. The effect of stress-related dose of dopamine (DA) was evaluated by addition of
1×10−6 M or 1×10−7 M of this neurotransmitter at beginning of cultures. In (A) the
proliferation was determined by the level of [
3
H] thymidin incorporation (cpm), while
in (B), the cell viability was evaluated by cell count in trypan blue. The p values are
indicated in the ﬁgure.2.5. Proliferation assay
Cultures containing approximately 1×106/mL of PBMC were
maintained for 3 days in the presence of PHA (1 μg/mL) or for
5 days with PPD (15 μg/mL). In some wells, stress-related doses of
both DA and DEX were added at beginning of the culture time. The
cellular proliferation was measured by [3H] thymidine incorporation,
added to cultures at 0.5 μCi/well 8 h before the end of the incubation
time. The cells were harvested in glass ﬁber ﬁlters in an automatic cell
harvester and radioactive incorporation was measured using a liquid-
scintillation counter. The results were shown as mean±sd of counts
per minute (cpm).
2.6. Viability test
In order to perform the viability test, PMBC (1×106/mL) were
seeded in a 24-well ﬂat-bottomedmicroplates and stimulated or with
PHA (1 μg/mL) for 3 days. In some wells, stress-related doses of both
DA and DEX were added at beginning of the time cultures. At the end
of culture time, the percentage of viable/unviable PBMC cultures was
evaluated by trypan blue exclusion test. Brieﬂy, 72 h after culturing,
50 μL of cell suspension was added to 50 μL of trypan blue (0.4%). The
mix was left approximately 3 min at room temperature. The cells
were then counted within 3 to 5 min of mixing with trypan blue using
a hemocytometer. Viable (unstained) and nonviable (stained) cells
and total (both) were counted. To verify the percentage (%) of viable
cells, we applied the following equation: viable cells (%)=total
number of viable cells per mL/total number of cells per mL×100.
2.7. Cytokine evaluation
In order to dose the in vivo and in vitro cytokine contents, the
plasma samples and the supernatants, collected from either PHA- or
PPD-stimulated PBMC cultures with or without DA, were submitted to
cytokine measurement by OptEIA ELISA kits (BD, Pharmigen, San
Diego), according to manufacturer's protocol. Furthermore, we
assayed the cytokine contents from these cell cultures following
addition of stress-related dose of DEX. Brieﬂy, each ELISA was
performed using pairs of mAbs directed to human IL-2, IL-1β, IL-6,Control GAD
0
2000
4000
6000
8000
None
PPD
PPD +
DA (1 x 10-6 M)
p< 0.0001
p= 0.834
cm
p
Fig. 2. The effect of dopamine (DA) on in vitro PPD-induced proliferative response in
anxious and non-anxious subjects. PBMC (1×106/mL) puriﬁed from anxious (GAD,
n=12) and non-anxious (control, n=15) individuals were kept in culture with only
medium (none) or with PPD (15 μg/mL) for 5 days. The effect of dopamine (DA) was
evaluated by addition of 1×10−6 M of this neurotransmitter at beginning of cultures.
The p values are indicated in the ﬁgure.
61T.B. Ferreira et al. / Journal of Neuroimmunology 238 (2011) 58–66IL-10, IL-4, IL-21, TNF-α, IFN-γ, TGF-β, and IL-17. The reaction was
revealed with streptavidin-horseradish peroxidase, using 3,3′,5,5′-
tetramethylbenzidine (TMB) as substrate. Recombinant human
cytokine ranging from 10 to 500 pg/mL was used to construct
standard curves.2.8. Statistical analysis
The statistical test for comparison between groups was the
nonparametric Kruskal–Wallis test with multiple comparisons (i. e.
immunological events induced in the presence of PHA, PHA/DA and
PHA/DA/DEX from healthy controls and GAD individuals). Com-
parison between two groups was performed using the nonpara-
metric Mann–Whitney U test. The Wilcoxon signed rank test was
used to assess changes within the group. The signiﬁcance in all
experiments was deﬁned as pb0.05.No
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Fig. 3. Th1/Th2 and Treg cytokines in anxious and control individuals in the presence or abse
(1×10−6 M), was added to PBMC cultures (1×106/mL) derived from anxious (GAD, n=20
after 3 days. In the ﬁgure, [A] indicates Th1 (IL-2 and IFN-γ), [B] shows Th2 (IL-4 and IL-5), a
bars within boxes correspond to the median; box limits correspond to 25th and 75th percent
were compared and the p values are indicated in the ﬁgure.3. Results
3.1. Impact of dopamine (DA) on proliferation of peripheral blood
mononuclear cells stimulated with either T cell polyclonal activator or
recall antigen
To investigate the impact of chronic stress on some immune
events, samples of peripheral blood were drawn from healthy
(control) and anxious individuals (GAD). As shown in the table, any
statistical difference was observed concerning the parameters
analyzed between control and GAD individuals, even the percentage
of CD4+ and CD8+ T cells, B cells (CD19+) and monocytes (CD14+).
Furthermore, no participant showed any detectable sign of current
infection unless 1 month before blood sampling.
The ﬁrst immune event analyzed in our study was the PHA-
induced T cell proliferation. As shown in Fig. 1A, the extent of T cell
proliferation was statistically lower in cultures from anxiousNo
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alone neither induced any detectable cell proliferation nor caused cell
death (data not shown). On the other hand, although DA had been able
to diminish the proliferation in control cell cultures, this neurotrans-
mitter did not change it in the GAD group (Fig. 1A). The lower cell
proliferation in the anxious-derived PBMC cultures might be related to
higher cell death, since the percentage of viable cells was signiﬁcantly
lower in the anxious group, as comparedwith control cultures (Fig. 1B).
Nevertheless, while the addition of DA signiﬁcantly reduced the cell
viability in PHA-activated cell cultures from non-anxious individuals
(control), this neurotransmitter did not change the viable cell yield in
anxious-derived PHA-activated PBMC (Fig. 1B). Of note, the similar
pattern concerning cell proliferation and viability was observed even
after addition of DA concentration 10 lower (Fig. 1).
Concerning the response to recall antigen PPD, the level of
thymidine uptake was also signiﬁcantly lower in GAD-derived cell
cultures (p=0.017) (Fig. 2). As observed by PHA-activated cell
cultures, the extent of PPD-induced lymphoproliferation was reduced
by DA only in the control group (Fig. 2).
3.2. Impact of dopamine (DA) on cytokine proﬁle in cell cultures from
control and anxious individuals
The type of acquired immune response is mainly determined by the
cytokinenetworkproducedby activated T cells. Therefore,we evaluated
the cytokine proﬁle of non-activated or activated cell cultures from the
two experimental groups. Of note, no detectable spontaneous release of
any cytokinewas observed in both experimental groupswithout PHAor
DA (data not shown). Following DA addition, very low, but detected,
levels of TNF-α (41±22 pg/mL) and IL-6 (37±21 pg/mL) were
observed only in anxious-derived non-activated cell cultures.No
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Fig. 4. The impact of dopamine (DA) on Th17 cytokines in anxious and control individual
individuals were maintained in cultures for 3 days in the presence of polyclonal T cell activa
3 days, the supernatants were collected and IL-1β (A), IL-6 (B), TNF-α (C), IL-21 (D), and (E) I
to the median; box limits correspond to 25th and 75th percentiles and vertical lines indicat
values are indicated in the ﬁgure.Following PHA stimulus, however, the production of the classical
Th1 cytokines, IL-2 and IFN-γ, was signiﬁcantly higher in cell cultures
from control individuals as compared with GAD ones (Fig. 3A). DA, on
the other hand, reduced signiﬁcantly the level of IL-2 and IFN-γ only
in cell cultures from the control group. Concerning IL-4 and IL-5, their
levels were also lower in PHA-activated cell cultures from anxious
individuals (Fig. 3B) and DA addition did not modify them neither in
control nor in anxious-derived cell cultures. Among the anti-
inﬂammatory cytokines, although both IL-10 and TGF-β production
had been lower in anxious-derived PHA-activated cell cultures, the
addition of DA was able to reduce the production of these anti-
inﬂammatory cytokines in the anxious group (Fig. 3C). Finally, we
performed the quantiﬁcation of cytokines related to Th17 phenotype,
particularly IL-17. As demonstrated in Fig. 4, the production of not
only IL-17 but also IL-21 and TNF-α were signiﬁcantly higher in the
anxious group. With regard to DA, this neurotransmitter signiﬁ-
cantly up-regulated the production of TNF-α and IL-6 from both
control and GAD groups (Fig. 4). Interestingly, DA enhanced IL-17
and IL-21 production only in PHA-activated cell cultures from
anxious subjects.
When we analyzed the cytokine proﬁle in PPD-activated PBMC
cultures, the IFN-γ levels were signiﬁcantly lower in the GAD group
and it was not changed by DA (Fig. 5). On the other hand, IL-17 and
TNF-α release in response to PPD was signiﬁcantly up-regulated by
DA addition.
Finally, whenwe analyzed the systemic cytokine proﬁle, IL-1β (41±
18 pg/mL×8±10 pg/mL, pb0.0001) and IL-6 (76±31 pg/mL×7±
12 pg/mL, pb0.0001) were signiﬁcantly higher in the anxious group.
Concerning the other cytokines, their levels were undetectable or
extremely low and the differences did not reach any statistical
difference.No
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Fig. 5. The impact of dopamine (DA) on PPD-induced cytokine production in anxious
and control individuals. PBMC (1×106/mL) obtained from non-anxious (control,
n=10) and anxious (DAG, n=10) individuals weremaintained in cultures for 5 days in
the presence of PPD (15 μg/mL) alone or with stress-related dose of DA (1×10−6 M). At
the end of 5 days, the supernatants were collected and IL-10, IFN-γ, and IL-17 were
evaluated by ELISA. In the ﬁgure, the horizontal bars correspond to the median. The
mean values of both groups were compared and the p values are indicated in the ﬁgure.
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in cultures from control and GAD individuals
Finally, our last objective was to evaluate the effect of a stress-
related dose of glucocorticoid (GC) on IL-21, TNF-α and IL-17
production by PHA-activated cell cultures in the presence of DA. As
shown in Fig. 5, while DEX (1×10−6 M) reduced IL-21, TNF-α and
IL-17 levels in control cell cultures, this glucocorticoid was not able to
down-regulate these pro-inﬂammatory cytokine production in the
anxious group. This GC-insensitivitywas also observed in PHA-activated
cell cultures even after addition of DEX concentration 10 higher
(1×10−5 M) (Fig. 6A). The presence of 1×10−7 M of DA did not change
this unresponsiveness to DEX (data not shown). Finally, the lower
sensitivity to DEX was also observed in the GAD-derived PPD-activated
cell cultures (Fig. 6B).
4. Discussion
Chronic stress damages the immune function and, consequently,
elevates the risk of infectious diseases (Boscarino, 2004; Koh and Lee,
2004; Sareen et al., 2005; Schneiderman et al., 2005; Zhou et al., 2005;
Godbout and Glaser, 2006; Arranz et al., 2007). As stressful life events
enhance the peripheral concentration of dopamine (DA) (Sinha,
2008), the objective of the present studywas to evaluate the impact of
a stress-related dose of DA on the functional proﬁle of T cells from
patients with generalized anxiety disorder (GAD). To our knowledge,
this is the ﬁrst report that investigates the effect of DA on individuals
with GAD.
Some studies have demonstrated that DA inhibits polyclonally-
activated T cell proliferation in cell cultures from healthy individuals
(Saha et al., 2001a,b). In our system, the in vitro proliferative response
induced by either T cell polyclonal activator or PPDwas higher in non-
anxious individuals, but, differently from GAD cell cultures, it was
reduced following DA addition. The reason by which DA attenuated
proliferative response in PHA-activated cell cultures from control
individuals could be related to its ability to reduce both cell viability
and IL-2 release. Study by Ghosh et al. (2003) demonstrated that DA,
through type I DARs, reduces the expression of tyrosine kinases Lck
and Fyn in polyclonally-activated T cells. Both enzymes are TCR-
dependent signaling molecules involved in IL-2 production (Mills et
al., 1993). Furthermore, Cosentino et al. (2004) also demonstrated
that type I DARs stimulation by stress-related doses of DA induced
apoptotic T cell death through oxidative stress in cell cultures from
healthy individuals. Although we have decided to show only the data
of 3 days of cell cultures (the peak of T cell response to mitogen), a
time-course evaluation also demonstrated lower cell viability 24 and
48 h after DA addition in non-anxious polyclonally-activated cell
cultures (data not shown). To date, we do not know why these
phenomena were not observed in GAD patients, but this could be
related to the lower type I DARs expression in anxious-derived T cells.
At the moment we are dedicating our efforts to investigate, by
cytometry, the expression pattern of DARs in the PBMC from anxious
patients.
It is known that an efﬁcient host defense against invading
pathogenic microorganisms is coordinated by the action of the highly
heterogeneous effector T cells. Th1-mediated response is character-
ized by the production of IL-2 and IFN-γ, and is involved mainly in
cellular immunity against intracellular microorganisms (Gutcher and
Becher, 2007). On the other hand, human Th2 cells produce IL-4, IL-5,
and IL-13 and are required to control helminthes by stimulating the
growth and activation of mast cells and eosinophils, as well as
differentiating B cells into IgE secreting cells (Ekkens et al., 2003).
Study by Ghosh et al. (2003) demonstrated that DA inhibited the anti-
CD3-induced release of both Th1 and Th2 cytokines from healthy
individuals. In our study, however, we observed that in control cell
cultures DA addition only down-regulated Th1 cytokines. A possibleexplanation for the absence of DA effect on Th2 phenotype in the
control group could be the exclusion in our study of all individuals
with high tendency to develop Th2 pattern, such as subjects with
chronic atopic disorders, like asthma and atopic dermatitis. Concern-
ing the anxious individuals, the production of Th1 cytokines by
polyclonally-activated T cells was signiﬁcantly lower than control
cultures, and it was not altered by DA addition. The Th1 phenotype
deﬁciency in GAD individuals, which was already recently published
by our group (Vieira et al., 2010), may clearly provide a reason by
which anxious individuals have greater susceptibility to infectious
diseases and malignancies (Cohen et al., 1993; Takkouche et al., 2001;
Ben-Eliyahu, 2003; Aviles et al., 2004). It is known that protection
against pulmonary TB is related to the ability of humans to develop a
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Fig. 6. The effect of glucocorticoid on DA-induced cytokine proﬁle from anxious and control individuals. DA (1×10−6 M) was added to the PBMC (1×106/mL) cultures, obtained
from anxious (GAD) and non-anxious (control) individuals, and maintained in (A) for 3 days in the presence of polyclonal T cell activator (PHA, 1 μg/mL) or in (B) for 5 days in the
presence of PPD (15 μg/mL). To evaluate the effect of glucocorticoid on the DA-induced cytokines in PHA-activated cell cultures, we added stress-related doses of dexamethasone
(DEX, at 1×10−6 M or 1×10−5 M) at the beginning of the cultures. After 3 days (PHA-activated) or 5 days (PPD-stimulated), the supernatants were collected and the cytokines were
evaluated by ELISA. The mean values without and with DEX were compared and the p values are indicated in the ﬁgure.
64 T.B. Ferreira et al. / Journal of Neuroimmunology 238 (2011) 58–66Th1 immune response (Marchant et al., 1999; Djuardi et al., 2010). In
fact, in our present study, we observed a lower IFN-γ production by
PPD-activated cell cultures from anxious individuals as compared
with control ones.
In our study, the most interesting result was the effect of DA on
Th17-related cytokines. Th17 cells produce not only IL-17 (also
referred to as IL-17A) but also IL-21, IL-1β, IL-6 and TNF-α, and play,
with the help of Th1 cells, important roles in the clearance of certain
microbes, particularly extracellular bacteria and fungi (Jovanovic et
al., 1998; Matsuzaki and Umemura, 2007) mainly by inducing
chemotaxis of neutrophils to sites of infection (Gutcher and Becher,
2007). Nevertheless, a dominate Th17 phenotype has also been
related to development of inﬂammatory disorders (Miossec, 2009).
Our results demonstrated that activated cell cultures from anxious
individuals produced higher Th17 related cytokines, particularly IL-
17, in response to T cell polyclonal activator. Interestingly, the in vitro
DA addition ampliﬁed Th17-related cytokine production from both
PHA- and PPD-stimulated GAD cell cultures. This same general pattern
in GAD group was also observed in earlier culture times (24 and 48 h)
(data not shown). In schizophrenic patients, where hyperdopaminer-
gic activity has been emphasized (Birtwistle and Baldwin, 1998), a
signiﬁcantly higher expression of DA D3 receptors has been described
in T cells (Ilani et al., 2001; Boneberg et al., 2006), and it appears to
correlate with increased plasma levels of IL-6, IL-1β and TNF-α (Maes
et al., 1995). In our study, the dosage of the cytokines in the plasma
showed low but signiﬁcantly higher IL-1β and IL-6 production in GADpatients, as compared with control ones. In agreement with this last
result, it is well established that anxiety is related to increased
circulating levels of IL-6, TNF-α, IL-1β and IL-8 (Afﬂeck et al., 1997;
Wilson et al., 1999; Muller and Schwarz, 2002; Sutherland et al., 2003;
von Känel et al., 2007; Wessa and Rohleder, 2007; Gill et al., 2008;
Lemieux et al., 2008; Gill et al., 2009). As revised by Khairova et al.
(2009), pro-inﬂammatory cytokines, such as TNF-α, are associated
with increased risk of anxiety and depression. Although dopamine has
been directly implicated in the mood disorders (Durant et al., 2010),
this neurotransmitters could indirectly elevate the risk of anxiety by
up-regulating the production of these cytokines in anxious subjects.
In contrast to control group, the DA-enhanced Th17 cytokine
production in either PHA- or PPD-activated anxious-derived cell
cultures was more resistant to stress-related doses of glucocorticoid,
known to inhibit Th1- and Th17-mediated immune response normal
individuals (Ashwell et al., 2000; Vazquez-Tello et al., 2010).
Glucocorticoid (GC) hormones, particularly cortisol, can suppress
inﬂammatory cytokine production by downregulating the activity of
the transcription factor nuclear factor kappa B (NFκB) (De Bosscher et
al., 2000). Although we did not measure the plasma or saliva cortisol,
in chronically stressed patients the hypothalamic–pituitary–adrenal
(HPA) axis is often hyperactivated, resulting in the persistent release
of high levels of cortisol (Arborelius et al., 1999; Holsboer, 2000). It is
believed that, after long periods of exposure to stress, glucocorticoid
resistance arises, primarily through a reduction of both sensitivity and
expression of GC receptors. This GC resistance compromises the
65T.B. Ferreira et al. / Journal of Neuroimmunology 238 (2011) 58–66physiological regulation of inﬂammatory responses by HPA axis,
leading to a high basal immune activation state (Gotovac et al., 2003;
De Kloet et al., 2007).
Finally, besidesGC resistancedemonstrated here, the excessive Th17
response in anxious individuals might also be a consequence of an
insufﬁcient immunoregulation by regulatory T cells, whose cytokines
were down-regulated by DA addition. Tight regulation of Th17 cells is
required for effective control and avoidance of immunopathological
phenomena (Costantino et al., 2008). Several lines of evidence have
demonstrated that ﬁne immunoregulation is largely performed by a
pool of regulatory T cells, including those producing IL-10 and TGF-β
cytokines (Vignali et al., 2008). In our system, GAD individuals showed
lower IL-10 andTGF-β levels in activated cell cultures, as comparedwith
control cultures, andDAaddition reduced signiﬁcantly theproductionof
them only in cell cultures from anxious individuals. Recent evidence
indicates that stimulation of type I DARs also favors the polarization of
naïve CD4+ T-cells toward Th17 cells (Birtwistle and Baldwin, 1998;
Nakano et al., 2009). Because Th17 and Treg cells are involved in
autoimmunity acting as auto-aggressive and protective cells respec-
tively, it is likely that type IDARs expressed onT-cells are involved in the
interface between autoimmunity and health. Therefore, our next step is
to identify, through selective DARs agonists and antagonists, the
involvement of different kinds of DARs on these immune disturbances
enhanced by stress-related doses of DA in anxious individuals.
Taken together, all results indicate that cells derived from anxious
individuals show Th1, Th2 and Treg responses damage associated with
elevated Th17 response that was ampliﬁed by stress-related dose of
dopamine (DA). The ability of DA to favor Th17-related cytokines may
be a reason for the higher susceptibility of anxious individuals to
autoimmune diseases.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.jneuroim.2011.06.009.
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